Crystal form of atorvastatin hemi-calcium and processes for...

Details Crystal form of atorvastatin hemi-calcium and processes for... Crystal form of atorvastatin hemi-calcium and processes for...

2006-12-13

2011-12-20

Havlin, Robert (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C514S423000

Reexamination Certificate

active

08080672

ABSTRACT:
Provided is a crystal form of atorvastatin hemi-calcium and processes for its preparation.

REFERENCES:
patent: 4681893 (1987-07-01), Roth
patent: 5003080 (1991-03-01), Butler et al.
patent: 5097045 (1992-03-01), Butler et al.
patent: 5124482 (1992-06-01), Butler et al.
patent: 5149837 (1992-09-01), Butler et al.
patent: 5216174 (1993-06-01), Butler et al.
patent: 5245047 (1993-09-01), Butler et al.
patent: 5273995 (1993-12-01), Roth
patent: 5280126 (1994-01-01), Butler et al.
patent: 5298627 (1994-03-01), Butler et al.
patent: 5385929 (1995-01-01), Bjorge et al.
patent: 5959156 (1999-09-01), Hagen et al.
patent: 5969156 (1999-10-01), Briggs et al.
patent: 6121461 (2000-09-01), McKenzie
patent: 6600051 (2003-07-01), Tully
patent: 6605636 (2003-08-01), Aronhime et al.
patent: 6605729 (2003-08-01), Byrn et al.
patent: 6992194 (2006-01-01), Lidor-Hadas et al.
patent: 7074818 (2006-07-01), Manne et al.
patent: 7144915 (2006-12-01), Byrn et al.
patent: 7144916 (2006-12-01), Aronhime et al.
patent: 7151183 (2006-12-01), Tessler et al.
patent: 7411075 (2008-08-01), Ayalon et al.
patent: 2002/0099224 (2002-07-01), Niddam et al.
patent: 2002/0115709 (2002-08-01), Aronhime et al.
patent: 2002/0183378 (2002-12-01), Aronhime et al.
patent: 2003/0114686 (2003-06-01), Van Der Schaaf et al.
patent: 2003/0212279 (2003-11-01), Tessler et al.
patent: 2003/0216584 (2003-11-01), Aronhime et al.
patent: 2004/0054193 (2004-03-01), Byrn et al.
patent: 2004/0106670 (2004-06-01), Blatter et al.
patent: 2004/0220255 (2004-11-01), Schaaf et al.
patent: 2004/0242899 (2004-12-01), Reddy et al.
patent: 2005/0004206 (2005-01-01), Aronhime et al.
patent: 2005/0090542 (2005-04-01), Aronhime et al.
patent: 2005/0209306 (2005-09-01), Jegorov et al.
patent: 2005/0282885 (2005-12-01), Tessler et al.
patent: 2006/0020137 (2006-01-01), Tessler et al.
patent: 2006/0063826 (2006-03-01), Lifshitz-Liron et al.
patent: 2006/0100446 (2006-05-01), Aronhime et al.
patent: 2006/0106231 (2006-05-01), Aronhime et al.
patent: 2006/0122403 (2006-06-01), Suri et al.
patent: 2006/0205805 (2006-09-01), Van Der Schaaf et al.
patent: 2006/0241169 (2006-10-01), Park
patent: 2007/0032665 (2007-02-01), Gudipati et al.
patent: 2008/0306282 (2008-12-01), Krzyzaniak et al.
patent: 2521776 (2003-01-01), None
patent: 0848704 (1998-06-01), None
patent: 0848705 (1998-06-01), None
patent: 1148049 (2001-10-01), None
patent: 1235799 (2002-09-01), None
patent: 1424324 (2004-06-01), None
patent: 1783113 (2007-05-01), None
patent: WO97/03958 (1997-02-01), None
patent: WO 97/03959 (1997-02-01), None
patent: WO 01/36384 (2001-05-01), None
patent: WO 02/41834 (2002-05-01), None
patent: WO 02/43732 (2002-06-01), None
patent: WO02/051804 (2002-07-01), None
patent: WO02/057229 (2002-07-01), None
patent: WO 03/004470 (2003-01-01), None
patent: WO 03/011826 (2003-02-01), None
patent: WO03/050085 (2003-06-01), None
patent: WO 03/070702 (2003-08-01), None
patent: WO03/082816 (2003-10-01), None
patent: WO2004/022053 (2004-03-01), None
patent: WO2004/043918 (2004-05-01), None
patent: WO2004/050618 (2004-06-01), None
patent: WO2005/026116 (2005-03-01), None
patent: WO2005/090301 (2005-09-01), None
patent: WO2005/105738 (2005-11-01), None
patent: WO2006/011041 (2006-02-01), None
patent: WO2006/045865 (2006-05-01), None
patent: WO 2006/048894 (2006-05-01), None
patent: WO2006/106372 (2006-10-01), None
patent: WO2007/070667 (2007-06-01), None
patent: WO2007/096903 (2007-08-01), None
patent: WO2007/133597 (2007-11-01), None
patent: WO2008/002655 (2008-01-01), None
US Pharmacopia #23, national formulary #18.
Morissette et al. Advanced Drug Delivery Reviews 56 (2004) 275-300.
Byrn et al., Pharm. Res., (1995) v. 12, n. 7, p. 945-54.
Brittain (Polymorphism in Pharmaceutical Solids, vol. 95, 1999, Taylor & Francis, Harry G. Brittain (Ed.), 427 pp.).
Tiwari et al., J. Pharm. Biomed. Anal., 43 (2007) 865-72.
Campbell Roberts et al., J. Pharm. Biomed. Anal., 28 (2002) 1149-59.
Hurst et al., Analytica Chimica Acta, 337 (1997), 233-52.
Baumann, K.L. et al.,Tetrahydron Letters, 1992, 33, 2283-2284.
Caira, M.R., “Crystalline Polymorphism of Organic Compounds,”Topics in Current Chemistry, (1998) vol. 198, pp. 163-208, Springer, Berlin, DE.
Lipid Research Clinics Program, “The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in Incidence of Coronary Heart Disease”,J.A.M.A., 1984, 351-74, vol. 251, No. 3.
Scandinavian Simvastatin Survival Study Group, “Randomised Trial of Cholesterol Lowering in 4444 Patients With Coronary Heart Disease: The Scandinavian Survival Study (4s)”,The Lancet, 1994, pp. 1383-1389, vol. 344.
Witztum, “Chapter 36: Drugs Used in the Treatment of Hyperlipoproteinemias”,Goodman&Gilman's The Pharmacological Basis of Therapeutics, 9thed., 1996, pp. 875-897.
International Search Report from PCT/US2006/047834, dated Jun. 1, 2007.
Caira, Mino R., “Crystalline Polymorphism of Organic Compounds,” Topics in Current Chemistry, 1998, vol. 198, pp. 163-208.
Llinàs, Antonio, and Goodman, Jonathan M., “Polymorph Control: Past, Present and Future,” Drug Discovery Today, Mar. 2008, vol. 13 (Nos. 5/6), pp. 198-210.
Japanese Office Action, dated Nov. 30, 2010, from corresponding Japanese Patent Application No. 2007-555403 and English-language translation thereof.
Taiwanese Office Action, dated Nov. 23, 2010, from corresponding Taiwanese Patent Application No. 095146783 and English-language translation thereof.

Affiliated with

Also associated with

Rating

Crystal form of atorvastatin hemi-calcium and processes for... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Crystal form of atorvastatin hemi-calcium and processes for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystal form of atorvastatin hemi-calcium and processes for... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4256699